JKJohn M. Kovarik

John M. Kovarik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John M. Kovarik has a total of 102 co-authors. Here are the top co-authors by number of shared publications:

  • Alan Slade

    Novartis Pharmaceuticals, Basel, Switzerland and East Hanover, NJ, USA

    6 shared publications
  • Robert L. Schmouder

    Novartis Pharmaceuticals, Exploratory Development, Basel, Switzerland

    5 shared publications
  • Daniel Neddermann

    Novartis Pharmaceuticals, Exploratory Development, Basel, Switzerland

    3 shared publications
  • Gilles‐Jacques Riviere

    Novartis Pharmaceuticals, Exploratory Development, Basel, Switzerland

    3 shared publications
  • Steve Maton

    Novartis Pharmaceuticals, Exploratory Development, Basel, Switzerland

    3 shared publications
  • Sylvie Stitah

    Novartis Pharmaceuticals, Basel, Switzerland and East Hanover, NJ, USA

    3 shared publications

Latest Publications

  • Pharmacokinetics of Sotrastaurin Combined With Tacrolimus or Mycophenolic Acid in De Novo Kidney Transplant Recipients

    by John M. Kovarik, Jürg U. Steiger, Josep M. Grinyo, Lionel Rostaing, Wolfgang Arns, Jacques Dantal, Pieter Proot, Klemens Budde

    Sotrastaurin is a protein kinase C inhibitor in the development for prevention of organ rejection after renal transplantation. In a multicenter phase 2 trial, 216 de novo renal transplant recipients were randomized to mycophenolic acid (MPA) with standard-exposure tacrolimus (treatment A, n=74), 200 mg sotrastaurin twice daily with standard-exposure tacrolimus (treatment B, n=76), or 200 mg sotrastaurin twice daily with reduced-exposure tacrolimus (treatment C, n=66). After month 3, tacrolimus was replaced with MPA in arms B and C. The longitudinal pharmacokinetics of sotrastaurin and tacrolimus were prospectively evaluated through month 6. Sotrastaurin predose drug concentration (C0) was 0.6±0.4 μg/mL and did not differ when combined with standard-exposure versus reduced-exposure tacrolimus (P=0.99) nor when tacrolimus was replaced by MPA (P=0.11). Sotrastaurin peak concentration was 1.6±0.6 μg/mL, and area under the drug concentration-time curve over a dosing interval (AUC) was 12.2±4.2 μg hr/mL. Intersubject variability in AUC was 27% and not significantly influenced by age (18-67 years), weight (47-121 kg), sex, or creatinine clearance (36-173 mL/min). Sotrastaurin C0 was positively correlated with AUC (r=0.62, P<0.0001). Sotrastaurin increased tacrolimus concentrations by a pharmacokinetic interaction inasmuch as the tacrolimus dose needed to achieve a given C0 was up to 47% lower when combined with sotrastaurin versus with MPA. Sotrastaurin pharmacokinetics were similar when combined with reduced-exposure or standard-exposure tacrolimus or with MPA. Tacrolimus exposure was significantly increased by sotrastaurin in the initial weeks posttransplant by a pharmacokinetic interaction.


  • Sotrastaurin single-dose pharmacokinetics in de novo liver transplant recipients

    by John M. Kovarik, Peter Neuhaus, Umberto Cillo, Markus Weber, Sylvie Stitah, Ewa Gatlik, Karin Meiser, Alan Slade

    P>Sotrastaurin is a protein kinase C inhibitor in development for prevention of rejection after liver transplantation. In a pharmacokinetic study, 13 de novo liver transplant recipients received 100 mg sotrastaurin once between days 1-3 and once between days 5-8 post-transplant. Sotrastaurin absorption based on the area under the concentration-time curve (AUC) of total drug in blood (3544 +/- 1434 ng center dot h/ml) was similar to that of healthy subjects in a previous study (4531 +/- 1650 ng center dot h/ml). However, the sotrastaurin binding protein, alpha 1-acid glycoprotein, was nominally higher in patients (1.07 +/- 0.28 vs. 0.87 +/- 0.16 g/l, P = 0.13) yielding a 60% lower AUC based on free drug versus that in healthy subjects (27 +/- 13 vs. 62 +/- 15 ng center dot h/ml, P < 0.0001). There was minor excretion of sotrastaurin in drained bile (1% of dose) consistent with the fact that sotrastaurin is extensively metabolized leaving little unchanged drug to excrete. In the first week after liver transplantation, sotrastaurin is bioavailable after oral administration. However, patients with elevated alpha 1-acid glycoprotein levels may have lower free drug concentrations. Whether a higher dose of sotrastaurin is needed to compensate for this in the short-term after surgery will be addressed in future clinical trials


  • Sotrastaurin and Tacrolimus Coadministration: Effects on Pharmacokinetics and Biomarker Responses

    by John M. Kovarik, Sylvie Stitah, Alan Slade, Alessandra Vitaliti, Frank Straube, Olivier Grenet, Serge Winter, Nikolaos Sfikas, Michael Seiberling

    Sotrastaurin is an immunosuppressant that inhibits protein kinase C. In the prevention of acute rejection in organ transplantation, sotrastaurin might be combined with tacrolimus. A drug interaction study was performed in 18 healthy subjects who received single oral doses of sotrastaurin 400 mg, tacrolimus 7 mg, and the drug combination. Drug blood levels and lymphocyte activation and proliferation were measured. Tacrolimus did not alter the pharmacokinetics of sotrastaurin; however, sotrastaurin increased tacrolimus area under the concentration-time curve by 2.0-fold (90% confidence interval, 1.8-2.1). Production of interleukin-2 and tumor necrosis factor by T cells activated via calcium-independent pathways was inhibited by 75% ± 22% from baseline by sotrastaurin. Interleukin-2 messenger RNA levels were decreased by 90% ± 9% from baseline by sotrastaurin. Addition of tacrolimus to sotrastaurin had minimal or no effect on these biomarkers, consistent with tacrolimus' mechanism of action. Lymphocyte proliferation induced via calcium-dependent pathways was decreased from baseline by 82% ± 9% by sotrastaurin, 76% ± 11% by tacrolimus, and 96% ± 2% for the drug combination. How sotrastaurin and tacrolimus could be partnered in an immunosuppressive regimen will need to be established in the context of controlled clinical trials in organ transplant patients, taking into account the pharmacokinetic interaction on tacrolimus and the potentially enhanced immunosuppressive activity of this drug combination.


  • Overview of Sotrastaurin Clinical Pharmacokinetics

    by John M Kovarik, Alan Slade

    Sotrastaurin (AEB071) is an investigational immunosuppressant that blocks T-lymphocyte activation through protein kinase C inhibition. It is currently in Phase II of clinical development for the prevention of acute rejection after solid organ transplantation. In renal transplant clinical trials, sotrastaurin has been administered at doses of 200 to 300 mg twice daily. Using a validated liquid chromatography method with tandem mass spectrometry, steady-state predose blood concentrations averaged approximately 600 and 900 ng/mL at these dose levels, respectively. Sotrastaurin is primarily metabolized through CYP3A4. There is one active metabolite, N-desmethyl-sotrastaurin, that is present at low blood concentrations (less than 5% of the parent exposure). The elimination half-life of sotrastaurin averages 6 hours. Clinical drug interaction studies to date have demonstrated that sotrastaurin increases the area under the concentration-time curve of everolimus 1.2-fold and of tacrolimus twofold. Conversely, sotrastaurin area under the concentration-time curve is increased up to 1.8-fold by cyclosporine and 4.6-fold by ketoconazole. Blood samples from renal transplant patients receiving sotrastaurin were stimulated ex vivo by protein kinase C-dependent pathways. Inhibition of cytokine production, expression of CD69, and thymidine uptake served as biomarkers that demonstrated the ability of sotrastaurin to inhibit T-cell activation and proliferation at the doses used in these studies. Phase II trials have paired sotrastaurin with tacrolimus, mycophenolic acid, or everolimus. The clinical and pharmacokinetic results of these and upcoming trials will determine the optimal immunosuppressive regimen to benefit from sotrastaurin's novel mechanism of action and whether therapeutic drug monitoring will be beneficial.


  • Sotrastaurin and cyclosporine drug interaction study in healthy subjects

    by John M. Kovarik, Sylvie Stitah, Alan Slade, Alessandra Vitaliti, Frank Straube, Olivier Grenet, Serge Winter, Nikolaos Sfikas, Michael Seiberling

    Introduction. Sotrastaurin is an immunosuppressant that inhibits protein kinase C and blocks T‐lymphocyte activation. The authors determined the effect of combining sotrastaurin with the calcineurin inhibitor cyclosporine on the pharmacokinetics and biomarker responses to both drugs. Methods. This was a randomized, 4‐period, crossover study in 20 healthy subjects who received single oral doses of (1) sotrastaurin 100 mg, (2) cyclosporine 400 mg, (3) 100 mg sotrastaurin with 100 mg cyclosporine and (4) 100 mg sotrastaurin with 400 mg cyclosporine. Blood samples were collected to measure drug levels and biomarkers of T‐lymphocyte activation (interleukin‐2 and tumor necrosis factor producing T‐cells and interleukin‐2 messenger RNA levels) and of T‐lymphocyte proliferation (thymidine uptake). Results. Sotrastaurin did not alter cyclosporine AUC; however, low‐dose and high‐dose cyclosporine increased sotrastaurin AUC by 1.2‐fold [90% confidence interval, 1.1–1.4] and 1.8‐fold [1.6–2.1], respectively. Adding high‐dose cyclosporine to a low‐therapeutic dose of sotrastaurin significantly enhanced the inhibition of cytokine production by 31% [95% confidence interval, 25–36%], of interleukin‐2 messenger RNA levels by 13% [7–19%], and of thymidine uptake by 37% [32–42%] compared with sotrastaurin alone. Addition of low‐dose cyclosporine elicited slightly lower enhancements in inhibition by 21% [14–28%], 6% [−4–16%], and 26% [21–30%], respectively, compared with sotrastaurin alone. Conclusions. Sotrastaurin did not alter the pharmacokinetics of cyclosporine, but cyclosporine increased sotrastaurin AUC up to 1.8‐fold. The combined drugs elicited a significantly greater inhibition of T‐cell activation and proliferation than sotrastaurin alone. Copyright © 2010 John Wiley & Sons, Ltd.


  • Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration

    by J.M. Kovarik, M. Bartlett, C. Rordorf, M.C. Antunes, S. Winter, P. Marbach, S. van Marle

    Sotrastaurin is an immunosuppressant that blocks T-lymphocyte activation via protein kinase C inhibition. The authors determined whether a pharmacokinetic interaction occurs between sotrastaurin and everolimus, both of which are substrates and inhibitors of CYP3A4. This was a randomized, three-period, crossover study in 18 healthy subjects. They received single oral doses of (1) 100 mg sotrastaurin, (2) 2 mg everolimus, and (3) the drug combination. Clinical and pharmacokinetic data were collected to Day 5 after each treatment. Coadministration of everolimus decreased sotrastaurin C(max) from 638 +/- 295 to 539 +/- 211 ng/ml yielding a combination/ monotherapy ratio (90% confidence interval) of 0.87 (0.76 - 1.00). Sotrastaurin total AUC was not altered by everolimus with values of 3660 +/- 1853 versus 3630 +/- 2006 ng*h/ml and a ratio of 1.00 (0.88 - 1.13). Sotrastaurin increased everolimus C(max) from 15 +/- 6 to 16 +/- 6 ng/ml yielding a ratio of 1.15 (0.99 - 1.33) and increased everolimus total AUC from 114 +/- 50 to 137 +/- 56 ng*h/ml yielding a ratio of 1.20 (1.05 - 1.37). The possibility that a higher dose of sotrastaurin than used in this study might further increase everolimus blood levels cannot be excluded. Coadministration of a single 100 mg dose sotrastaurin with a single 2 mg dose everolimus did not alter sotrastaurin pharmacokinetics to a clinically relevant extent. Everolimus AUC was increased 20% by sotrastaurin.


  • Open Access

    The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole

    by John M. Kovarik, Hsun-Lun A. Huang, Alan Slade, Nikos Sfikas, Patricia A. Chandler


  • The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects

    by John M. Kovarik, Alan Slade, Gilles‐Jacques Riviere, Daniel Neddermann, Steve Maton, Thomas L. Hunt, Robert L. Schmouder

    The authors determined whether intravenous atropine can prevent or counteract the negative chronotropic effect of the immunomodulator fingolimod. In this randomized, placebo-controlled, two-period, crossover study, 12 healthy subjects received 5 mg fingolimod orally concurrently with intravenous atropine (titrated to a heart rate of 110-120 beats min(-1)) or intravenous placebo. A second group of 12 subjects received atropine/placebo 4 h after the fingolimod dose. Continuous telemetry measurements were made for 24 h after each fingolimod dose. Fingolimod administration alone yielded a heart rate nadir of 51 +/- 5 beats min(-1) at a median 4 h postdose with heart rate remaining depressed at 51-64 beats min(-1) over the rest of the day. Concurrent administration of fingolimod and atropine yielded a nadir of 66 +/- 6 beats min(-1) resulting in an atropine: placebo ratio (90% confidence interval) of 1.30 (1.22, 1.36). When atropine was administered at the time of the nadir, it was able to reverse the negative chronotropic effect of fingolimod from a heart rate of 56 +/- 9 beats min(-1) (placebo) to 64 +/- 8 beats min(-1) (atropine) resulting in an atropine: placebo ratio of 1.15 (1.04, 1.26). Atropine had no influence on the pharmacokinetics of fingolimod. Atropine administered concurrently with fingolimod prevented the heart rate nadir that typically occurs 4 h postdose. Atropine administered at the time of the heart rate nadir was able to reverse the negative chronotropic effect of fingolimod.


  • A Mechanistic Study to Assess Whether Isoproterenol Can Reverse the Negative Chronotropic Effect of Fingolimod

    by Joh M. Kovarik, Gilles‐Jacques Riviere, Daniel Neddermann, Steve Maton, Thoma L. Hunt, Rober L. Schmouder

    The sphingosine‐1‐phosphate receptor modulator fingolimod (FTY720) elicits a negative chronotropic effect at treatment initiation that attenuates thereafter. The authors determined whether isoproterenol can counteract this effect. In this randomized, crossover study, 14 healthy subjects received 5 infusions of isoproterenol (titrated to increase heart rate to 100–120 bpm) or intravenous placebo. The first infusion was 2 hours before and the other 4 infusions were between 3 and 6 hours after a 5‐mg oral dose of fingolimod. Telemetry and pharmacokinetic data were collected for 24 hours. During isoproterenol infusion 1 (before fingolimod administration), heart rate was increased 80% from preinfusion 68 ±9 bpm to a maximum 122 ± 15 bpm. Administration of fingolimod decreased heart rate from 73 ± 11 bpm predose to a nadir of 57 ± 8 bpm. The subsequent isoproterenol infusion 2 in the presence of fingolimod increased mean heart rate by 85% to a maximum 105 ±21 bpm. A 41% higher total isoproterenol dose was needed to increase heart rate to the target range with fingolimod (97 ± 6 mcg) compared with isoproterenol alone (69 ± 27 mcg). Isoproterenol infusions 3 to 5 had similar effects on heart rate as infusion 2. Fingolimod had no significant influence on blood pressure responses to isoproterenol. Isoproterenol did not alter the pharmacokinetics of fingolimod. The pure beta‐agonist isoproterenol can reverse the heart rate reduction that occurs transiently after initiating fingolimod treatment.